Claims:

1. Use of an anti-C1q antibody in the manufacture of a medicament for the treatment of an ocular disease in a human patient, wherein the medicament is for intravitreal injection at a dose of about 1 mg to about 10 mg, and

wherein the antibody comprises a light chain variable domain comprising an HVR-L1 having the amino acid sequence of SEQ ID NO: 5, an HVR-L2 having the amino acid of SEQ ID NO: 6, and an HVR-L3 having the amino acid of SEQ ID NO: 7; and a heavy chain variable domain comprising an HVR-H1 having the amino acid sequence of SEQ ID NO: 9, an HVR-H2 having the amino acid of SEQ ID NO: 10, and an HVR-H3 having the amino acid of SEQ ID NO: 11.

2. The use of claim 1, wherein the antibody comprises a light chain variable domain comprising an amino acid sequence with at least about 95% homology to the amino acid sequence selected from SEQ ID NO: 4 and 35-38 and wherein the light chain variable domain comprises an HVR-L1 having the amino acid sequence of SEQ ID NO: 5, an HVR-L2 having the amino acid of SEQ ID NO: 6, and an HVR-L3 having the amino acid of SEQ ID NO: 7.

3. The use of claim 2, wherein the light chain variable domain comprises an amino acid sequence selected from SEQ ID NO: 4 and 35-38.

4. The use of any one of claims 1-3, wherein the antibody comprises a heavy chain variable domain comprising an amino acid sequence with at least about 95% homology to the amino acid sequence selected from SEQ ID NO: 8 and 31-34 and wherein the heavy chain variable domain comprises an HVR-H1 having the amino acid sequence of SEQ ID NO: 9, an HVR-H2 having the amino acid of SEQ ID NO: 10, and an HVR-H3 having the amino acid of SEQ ID NO: 11.

5. The use of claim 4, wherein the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NO: 8 and 31-34.

6. The use of any one of claims 1-5, wherein the antibody is a monoclonal antibody, a humanized antibody, a human antibody, a chimeric antibody, an antibody fragment, or antibody derivative thereof.

7. The use of claim 6, wherein the antibody is an antibody fragment and the antibody fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule.

8. The use of claim 7, wherein the Fab fragment comprises a heavy chain Fab fragment of SEQ ID NO: 39 and a light chain Fab fragment of SEQ ID NO: 40.

9. The use of any one of claims 1-8, wherein the medicament is for administration once a week, once every other week, once every three weeks, once a month, once every four weeks, once every six weeks, once every 8 weeks, once every other month, once every 10 weeks, once every 12 weeks, once every three months, or once every 4 months.

10. The use of claim 9, wherein the medicament is for administration for at least 3 months, at least 4 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, or at least 12 months.

11. The use of claim 9 or 10, wherein the medicament is for administration for 12 months.

12. The use of any one of claims 1-11, wherein the dose comprises about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, or about 10 mg of the anti-C1q antibody.

13. The use of any one of claims 1-12, wherein the dose comprises about 1 mg of the anti-C1q antibody.

14. The use of any one of claims 1-12, wherein the dose comprises about 2.5 mg of the anti-C1q antibody.

15. The use of any one of claims 1-12, wherein the dose comprises about 5 mg of the anti-C1q antibody.

16. The use of any one of claims 1-12, wherein the dose comprises about 2 mg of the anti-C1q antibody.

17. The use of any one of claims 1-12, wherein the dose comprises about 10 mg of the anti-C1q antibody.

18. The use of any one of claims 1-12, wherein the dose comprises about 1 mg to about 2.5 mg, about 2.5 mg to about 5 mg, about 5 mg to about 7.5 mg, or about 7.5 mg to about 10 mg of the anti-C1q antibody.

19. The use of any one of claims 1-18, wherein the ocular disease is glaucoma or age-related macular degeneration.

20. The use of claim 19, wherein the age-related macular degeneration is geographic atrophy.